

MEDICARE PART D OPIOIDS ER PRESCRIBER FAX FORM

ONLY the prescriber may complete this form. This form is for Medicare Part D prospective, concurrent, and retrospective reviews.

Please fax or mail this form to: TOLL FREE Fax: 855-212-8110 Phone: 800-693-6651	Prime Therapeutics LLC Attn: Medicare Appeals Department 2900 Ames Crossing Road Suite 200 Eagan, MN 55121
---	---

The following documentation is **REQUIRED**. For formulary information, please visit www.myprime.com and search for the appropriate health plan formulary. To submit this form electronically, please click [here](#) or go to covermymeds.com.

Per CMS requirements – all standard requests are completed within 72 hours (including weekends)
 If you request an expedited review, you certify that applying the 72-hour standard review time frame could seriously harm the patient's life, health or ability to regain maximum function. Please check the box to request an expedited review:

PATIENT, INSURANCE and PRESCRIBER/CLINIC INFORMATION

Today's Date: _____

Patient Name (First):	Last:	M:	DOB (mm/dd/yy):
Insurance ID Number:		Patient Telephone Number:	
Prescriber Name:	Prescriber NPI#:	Specialty:	Clinic Contact Person's Name:
Clinic Name:		Clinic Address:	
City, State, Zip:		Clinic Phone #:	Clinic Secure Fax #:
Is the patient a long term care facility resident? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, please provide the LTC facility contact's name, telephone and fax numbers			
LTC Contact Name:		LTC Phone #:	LTC Secure Fax #:
Patient's Diagnosis (ICD code, plus description):			
Medication Requested:		Strength:	
Dosing Schedule:		Quantity per Month:	
1. Is the patient currently treated with the requested medication? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, when was treatment with the requested medication started? _____			
2. Is the medication being prescribed as an as-needed analgesic? <input type="checkbox"/> Yes <input type="checkbox"/> No			
3. Does the prescriber have a patient-specific pain management plan on file for the patient (please attach the patient's medical history including pharmacological and non-pharmacological therapies)?..... <input type="checkbox"/> Yes <input type="checkbox"/> No			
4. Does the patient have any FDA-labeled contraindications to the requested agent? <input type="checkbox"/> Yes <input type="checkbox"/> No			
5. Has the prescriber reviewed the patient's records in the state's prescription drug monitoring program (PDMP) AND determined that the opioid dosages and combinations of opioids and other controlled substances within the patient's records do NOT indicate the patient is at high risk for overdose? <input type="checkbox"/> Yes <input type="checkbox"/> No			
6. Does the patient's medication history include use of an immediate-acting opioid? <input type="checkbox"/> Yes <input type="checkbox"/> No If no, does the patient have an intolerance or hypersensitivity to an immediate-acting opioid? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, please explain: _____ _____ If no, does the patient have an FDA labeled contraindication to an immediate-acting opioid? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, please specify: _____ _____			
7. Please list all reasons for selecting the requested medication, dosing schedule, and quantity over alternatives (e.g., contraindications, allergies or history of adverse drug reactions to alternatives, lower dose tried). _____ _____			
8. Please list all the medications the patient has tried and failed for treatment of this diagnosis: _____ Date(s): _____ Date(s): _____ _____ Date(s): _____ Date(s): _____			
9. Please list any other medications the patient will use in combination with the requested medication for treatment of this diagnosis. _____ _____			

CONFIDENTIALITY NOTICE: This communication is intended only for the use of the individual entity to which it is addressed and contains information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 866-202-3474 and return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.